Received Sep 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No patient symptoms were reported/No additional AE; Nurse called and reported that a 20 year old patient received their 1st dose of GARDASIL 9 in 2017 and their 2nd dose in March of 2025. Caller stated the patient has not yet received a 3rd dose. Caller stated no patient symptoms were reported. No add; This spontaneous report was received from a nurse and refers to a 20-year-old female patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On an unknown exact date in 2017, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #, expiration date, exact dose route of administration and anatomical location were not provided) for prophylaxis. On an unknown exact day in March 2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #, expiration date, exact dose route of administration and anatomical location were not provided) for prophylaxis ( inappropriate schedule of product administration). No additional adverse event reported (no adverse event).